Johnson & Johnson, FDA
Rare vaccine side effect reported by J&J . FDA adds warning for Guillain-Barre syndrome.
Where: United States
▪ The US Food and Drug Administration (FDA) added a warning for a rare autoimmune condition, Guillain–Barre syndrome (GBS), in its Johnson & Johnson vaccine fact sheet for healthcare providers, caregivers, and recipients.
▪ On July 12th, Johnson & Johnson issued a press release updating its COVID-19 vaccine Factsheet to include the Guillain–Barre syndrome as a side effect.
▪ Johnson & Johnson stated, “Rare cases of the neurological disorder, Guillain-Barre syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination.”
▪ The statement continued, “While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barre syndrome.”
▪ Bacterial or viral infection generally triggers GBS – the disease can cause tingling, muscle weakness, and paralysis in adverse cases as the patient’s immune system attacks its own nerves.
▪ According to the Centers for Disease Control and Prevention (CDC), “An estimated 3,000-6,000 people develop GBS each year in the United States.”
Direct, authoritative source material on this story.
Articles Citable has ingested related to this story.
Percentage of day’s news
Citable analysis assessing the language of each article related to the story as positive, negative or neutral.
Publications covering this story along with their cumulative positive or negative sentiment.